Table 4 Distributions used in the model

Triangular

Percent_major_complications_surgery

Percent of patients experiencing a major complication from surgergy

0.045

0.09

Triangular

Percent_major_complications_LITT

Percent of major complications resulting from LITT procedure

0.0

0.027

Uniform

Percent_GTR_biopsy

Percentage of patients who have a GTR with biopsy

0.0

0.45

Uniform

Percent_major_complications_biopsy

Percent of major complications resulting from stereotactic biopsy

0.031

0.064

Uniform

Percent_unresectable_rGBM_surgery

Percent of recurrent GBMS that are unresectable with open craniotomy surgery

0.23

0.38

Uniform

Percent_open_resection_total

Percent of eloquent areas of brain where a total resection was achieveable

0

0.23

Uniform

OS_EOR_biopsy

Overall survival in months with biopsy based on an assumed extent of resection of <=70 %

4.85

12

Triangular

OS_EOR_STR

Overall survival in months with Subtotal Resection biopsy or craniotomy based on an assumed extent of resection of >=85 %

9.7

10.9

Triangular

OS_EOR_GTR

Overall survival in months with Subtotal Resection biopsy or craniotomy based on an assumed extent of resection of >=98 %

11.4

13.1

Uniform

Added_Survival_SRS

Additional overall survival in months with use of SRS in patients who have a KPS >=70

7.5

8.5

Uniform

OS_recurrent_Diffuse_GBM

Overall survival of recurrent diffuse GBM

6

7

Normal

PFS_LITT_GTR

Progession free survival using LITT—assuming GTR

12.2

13.6

Normal

PFS_LITT_STR

Progression free survival using LITT with subtotal resection

7.4

7

Normal

PFS_biopsy_GTR

Progession free survival using biopsy with GTR

12.2

13.6

Normal

PFS_biopsy

Progression free survival using biopsy with inadequate resection

4.8

5.2

Normal

PFS_surgery_GTR

Progression free survival with surgery and GTR

12.2

13.6

Normal

PFS_surgery_STR

Progression free survival with surgery with STR

7.4

7

Normal

LOS_surgery_GBM

Average LOS and std dev for GBM procedures under DGR 26; 2012 data

6.55

1.77

Uniform

Timing_follow_on_chemo_TMZ

Amount of time in days of follow on TMZ chemotherapy

180

360

Normal

Incremental_survival

Incremental overall survival with implanting a carmustine wafer versus not

3.3

4.467

Triangular

Percent_neuro_comps_0_to_3_mths_surgery

Percent of neurological complications (motor and cognitive lasting 0–3 months requiring rehabilitation; independent of major complications =>4 months

0.06

0.068

Uniform

Percent_neuro_comps_0_to_3_mths_LITT

Percent of neurological complicaitons (motor and cognitive lasting 0–3 months requiring rehabilitation; independent of major complications =>4 months

0

0.02

Uniform

Percent_Gliadel_wafer_implantations

Percent of time a Gliadel wafer implanted in a patient for treating brain cancer

0.1

0.33